Caroline Tanner, MD, PhD, FAAN, Weill Institute for Neurosciences, University of California, San Francisco, CA, talks on the use of amantadine in Parkinson’s disease. Initially, the drug was used as a prophylactic agent against influenza, serendipitously discovered to have anti-parkinsonian effects. Amantadine is an oral NMDA receptor antagonist and was the first agent approved by the FDA for the treatment of levodopa-induced dyskinesia following demonstration of its anti-dyskinetic effects. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.